<DOC>
	<DOCNO>NCT01226420</DOCNO>
	<brief_summary>Alefacept drug tht may reduce number T cell circulation . This drug use treatment psoriasis , skin disorder also cause T cell , like chronic GVHD . Information study psoriasis patient GVHD suggest drug may help treat chronic GVHD . Chronic GVHD medical condition develop allogeneic stem cell transplantation . It occur donor immune cell ( `` graft '' ) attack damage organ tissue ( `` host '' ) . It think T cell , subtype immune cell , responsible tissue damage chronic GVHD . In research study look see well Alefacept work treat chronic GVHD resolve therapy corticosteroid .</brief_summary>
	<brief_title>Alefacept Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease</brief_title>
	<detailed_description>- During first week treatment , participant receive 2 dos Alefacept intravenously ( Day 1 Day 4 ) . During week 2-12 , Alefacept give subcutaneously weekly . - On week 1 , 2 every week Week 12 study treatment , participant physical exam , blood test , ask general health specific question problem may . - Every week , participant ask complete questionnaire physical symptom , activity level emotional well .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>18 year age old Diagnosed cGVHD accord NIH criterion Active cGVHD despite treatment corticosteroid AND one additional immunosuppressive agent least 4 week , within 52 week enrollment . Subject recipient relate unrelated BMT PBSCT Subject underwent transplantation least 6 month prior enrollment Subject stable immunosuppressive regimen 2 week prior enrollment . Adjustment immunosuppressive medication maintain therapeutic level permit . Female child bear potential must negative pregnancy test prior first dose alefacept must agree practice effective contraception study . Men must also agree use adequate contraception prior study entry duration study . Meets medication restriction requirement agree follow medication restriction study . Received donor lymphocyte infusion precede 100 day Currently undergo ECP Subject recipient relate unrelated UCB Subject bronchiolitis obliterans , bronchiolitis obliterans organize pneumonia cryptogenic organize pneumonia sole manifestation cGVHD Uncontrolled intercurrent active infection . Absolute neutrophil count &lt; 1000/L AST , ALT total bilirubin &gt; 2x institutional upper limit normal unless manifestation GVHD Recurrent progressive malignancy time HCT , applicable individual malignancy Subject clinical study within last 30 day Receipt 5 prior agent treat cGVHD Known hypersensitivity alefacept component study medication Known positive human immunodeficiency virus ( HIV ) antibodies Currently enrol study chronic GVHD treatment receive treatment study previous participation study . Pregnant nursing Concurrent illness , opinion Investigator , may interfere treatment evaluation safety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>GVHD</keyword>
	<keyword>Alefacept</keyword>
	<keyword>Amevive</keyword>
</DOC>